Injectable Antiretroviral Drugs: Back to the Future

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities

(2020) Yubin Liu et al.   Emerging Microbes & Infections

Cabotegravir, a new option for PrEP

(2020) Tony Kirby   LANCET INFECTIOUS DISEASES

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

(2020) Bin Su et al.   CHINESE MEDICAL JOURNAL

Ibalizumab: A novel monoclonal antibody for the management of multidrug resistant HIV-1 infection

(2019) Mario V. Beccari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correction to: Ibalizumab: First Global Approval

(2018) Anthony Markham   DRUGS

Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy

(2018) Roberta Prinapori et al.   EPIDEMIOLOGY AND INFECTION

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Long-Acting Antiretrovirals: Where Are We now?

(2017) Amesika N Nyaku et al.   Current HIV/AIDS Reports

Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience

(2016) Tristan Delory et al.   JOURNAL OF MEDICAL VIROLOGY

HIV drug interaction resources from the University of Liverpool

(2016) Jane Chiodini   Travel Medicine and Infectious Disease

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

(2016) Hongwei Zhang et al.   AIDS Research and Therapy

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

(2015) R Verloes et al.   HIV MEDICINE

Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports

(2014) Lucia Taramasso et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Past, present and future: 30 years of HIV research

(2013) Françoise Barré-Sinoussi et al.   NATURE REVIEWS MICROBIOLOGY

Long-acting injectable antiretrovirals for HIV treatment and prevention

(2013) William R. Spreen et al.   Current Opinion in HIV and AIDS

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor

(2012) Huihui Chong et al.   PLoS One

The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research

(2011) Rony Zachariah et al.   Journal of the International AIDS Society

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

(2010) R. Song et al.   JOURNAL OF VIROLOGY

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers

(2008) L. Durand-Gasselin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY